Neuland Laboratories said the first module of a new commercial peptide manufacturing facility at its Bonthapally campus will be operational this summer, offering multi‑kiloliter LPPS and SPPS reactor capacity and targeting demand from GLP‑1 and other long‑chain peptide programs. The site targets both innovator and emerging biotech customers facing tightening peptide supply chains. Separately, Lonza announced a strategic divestment of its Capsules & Health Ingredients (CHI) business to Lone Star, retaining a minority stake while freeing capital to focus on CDMO core capabilities. Together, these moves highlight continued industry investment in specialized manufacturing capacity for peptides, cell & gene therapies and large‑molecule biologics, while larger CDMOs refine portfolios to prioritize high-margin, complex biologics services. Named sources: Neuland Laboratories statements and Lonza divestment announcement. For context: peptide therapeutics (e.g., GLP‑1 analogs) are driving demand for specialized large‑scale peptide synthesis capacity, and CDMO portfolio optimization reflects the capital intensity and strategic focus of modern biologics manufacturing.